Cover Image
Market Research Report

Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2017

Published by Global Markets Direct Product code 410980
Published Content info 73 Pages
Immediate Delivery Available
Price
Back to Top
Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2017
Published: June 27, 2017 Content info: 73 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 11 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 1 molecules, respectively.

Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC9452IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Virus, H7N9 Subtype Infections - Overview
    • Influenza A Virus, H7N9 Subtype Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Cocrystal Pharma Inc
    • EpiVax Inc
    • Fab'entech SA
    • Genentech Inc
    • GlaxoSmithKline Plc
    • iBio Inc
    • Inovio Pharmaceuticals Inc
    • Medicago Inc
    • Medigen Vaccine Biologics Corp
    • Nanotherapeutics Inc
    • NanoViricides Inc
    • NewLink Genetics Corp
    • Novavax Inc
    • Sanofi Pasteur SA
    • Visterra Inc
    • Vivaldi Biosciences Inc
  • Influenza A Virus, H7N9 Subtype Infections - Drug Profiles
    • AT-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-42344 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FBF-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3206640A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] (virus like particle, monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-295 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mRNA-1851 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Neuraminidase A for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIS-410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Influenza A Virus, H7N9 Subtype Infections - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Fab'entech SA, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Genentech Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by iBio Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medicago Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Nanotherapeutics Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by NewLink Genetics Corp, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Novavax Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Visterra Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Pipeline by Vivaldi Biosciences Inc, H1 2017
  • Influenza A Virus, H7N9 Subtype Infections - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top